Allogene Therapeutics

Allogene Therapeutics

ALLO· Manufacturing· Fiscal year ends in December

CEO pay in FY2022Stock -57.8% in FY2022

David Chang, M.D., Ph.D. is the CEO of Allogene Therapeutics and was paid $14.8M in FY2022 (Dec), up 46%.

Pay$100 in the stock at the end of FY20 → $25
CEO pay is from each Allogene Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1David Chang, M.D., Ph.D.FY2022
  2. 2Geoffrey ParkerNot disclosed
  3. 3Zachary J. Roberts, M.D., Ph.D.Not disclosed

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Allogene Therapeutics paid CEO David Chang, M.D., Ph.D. $14.8M in FY2022 (Dec). No other named executive of that year is on file.

Name
David Chang, M.D., Ph.D.President and Chief Executive Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers20

See all

The FY2025 (Dec) proxy of Allogene Therapeutics names 20 peer companies for pay. Pay versus performance data of Allogene Therapeutics for that year is not on file, so it has no rank.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board3

See all
  • Franz Humer, Ph.D.Lead independent director · 7 yr on the boardIndependentCompensation (Chair), International and Business Development Oversight (Chair)—Paid as an executive
  • John DeYoungDirector · 7 yr on the boardIndependentCompensation, International and Business Development Oversight—Paid as an executive
  • Owen Witte, M.D.Director · 7 yr on the boardIndependentNominating and Corporate Governance (Chair), Research and Development (Chair)—Paid as an executive

The board of the latest proxy (FY2025).

Activity

Filings6

See all
Proxy statementDEF 14AApr 30, 2026FY2025
Annual report10-KMar 12, 2026FY2025
Proxy statementDEF 14AApr 30, 2025FY2024
Annual report10-KMar 13, 2025FY2024
Proxy statementDEF 14AApr 23, 2024FY2023
Annual report10-KMar 14, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data